Metraipolis › archive › dc_53d2f79fcb88

Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study — Europe PMC PMID:42266700

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42266700
DOI
10.3389/fimmu.2026.1730742
License (as archived)
solo-consultazione
Archived
2026-11-01T08:19:35.615Z
SHA-256 of the archived text
7ab8b409eb5c5299495da1009ecc8fb8f78226774aa5b52e80a2699d38f1e218
Stable URL of this page
https://metraipolis.com/documento/dc_53d2f79fcb88

How to cite

Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study — Europe PMC PMID:42266700 — Europe PMC (en), https://europepmc.org/article/MED/42266700 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_53d2f79fcb88 (Metraipolis archive dc_53d2f79fcb88, sha256 7ab8b409eb5c5299495da1009ecc8fb8f78226774aa5b52e80a2699d38f1e218)
BibTeX
@misc{dc53d2f79fcb88,
  title = {Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study — Europe PMC PMID:42266700},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42266700},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_53d2f79fcb88; sha256 7ab8b409eb5c5299495da1009ecc8fb8f78226774aa5b52e80a2699d38f1e218},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42266700. Agents can read the archived copy with the MCP tool read_document.